Celularity (CELU) Cash from Operations Growth (1y) (2020 - 2025)
Celularity (CELU) Cash from Operations Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 42.76% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.58% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 151.70% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 172.77% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 56.79% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 100.14% |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | -420.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -420.14% |
| Sep 30, 2025 | -2,788.19% |
| Jun 30, 2025 | 71.03% |
| Mar 31, 2025 | 32.02% |
| Dec 31, 2024 | 136.72% |
| Sep 30, 2024 | 98.27% |
| Jun 30, 2024 | 68.73% |
| Mar 31, 2024 | 70.64% |
| Dec 31, 2023 | 85.33% |
| Sep 30, 2023 | 77.94% |
| Jun 30, 2023 | 69.64% |
| Mar 31, 2023 | 56.22% |
| Dec 31, 2022 | 7.68% |
| Sep 30, 2022 | -8.48% |
| Jun 30, 2022 | -99.55% |
| Mar 31, 2022 | -36.57% |
| Dec 31, 2021 | -90.39% |
| Sep 30, 2021 | 23.73% |
| Jun 30, 2021 | -8,009.32% |
| Mar 31, 2021 | -4,463.51% |